Tirzepatide + BPC-157 contains: Tirzepatide (Dual GIP/GLP-1 Agonist), BPC-157 (Body Protection Compound)
Future studies should prioritize (1) isolating and characterizing the active compounds within these botanicals, (2) elucidating their precise molecular targets (e.g., thyroid peroxidase, sodium-iodide symporter, cytokine signaling pathways), and (3) conducting well-designed controlled clinical trials to rigorously evaluate their safety and efficacy in human patients
Generation of hMSC cells in the Ryan lab was supported by 19/FFP/6446Research Ireland Frontiers for the future award
Oral glutathione supplements have poor bioavailability, meaning the body lacks an efficient method of absorbing the compound for use
GLP-1 agonist benefits are multiple regarding blood glucose control in the form of reducing Hemoglobin A1c (HBA1c) by 1.1%-1.6%, reducing postprandial excursions, and decreasing weight
Ng TF, Dawit K, Taylor AW